This KDO-8-P synthase inhibitor and potential antibiotic (FW = 217.29 g/mol), also named 6H-6-imino(2,3,4,5-tetrahydropyrimido)[1,2-c][1,3] benzothiazine, is a slow, tight-binding agent that targets 3-deoxy-D-mannooctulosonate-8-phosphate synthase, an enzyme participating in the synthesis of 3-deoxy-D-manno-2-octulosonic acid (KDO). The latter is an essential component of LPS (lipopolysaccharide) in the outer membrane of Gramnegative bacteria. PD 404182 is an antiretroviral agent with submicromolarinhibitory activity against human immunodeficiency virus-1 (HIV-1) and HIV-2 infection. PD-404182 also potently inhibits dimethylarginine dimethylaminohydrolase isoform-1 (DDAH1), the human enzyme that degrades Asymmetric Dimethylarginine, or ADMA (See Asymmetric Dimethylarginine). Because ADMA inhibits nitric oxide synthesis and because ADMA levels are predictive for future cardiovascular disease, chronic use of PD-404182 is apt to have side-effects.
